Savara Inc (NASDAQ:SVRA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Savara Inc (NASDAQ:SVRA) have earned a consensus rating of “Buy” from the six analysts that are covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $11.00.

Several research firms have recently weighed in on SVRA. Evercore ISI lowered their target price on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, May 16th. Oppenheimer upped their price objective on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. HC Wainwright lifted their target price on shares of Savara from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. JMP Securities restated a “market outperform” rating and set a $8.00 price target on shares of Savara in a research report on Monday, May 6th. Finally, Guggenheim raised their price target on Savara from $8.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 27th.

Institutional Trading of Savara

A number of hedge funds and other institutional investors have recently modified their holdings of SVRA. CANADA LIFE ASSURANCE Co acquired a new position in Savara during the 1st quarter worth $35,000. AJOVista LLC bought a new position in Savara in the fourth quarter valued at about $40,000. Choreo LLC bought a new position in Savara in the second quarter valued at about $59,000. China Universal Asset Management Co. Ltd. acquired a new stake in Savara in the fourth quarter worth about $74,000. Finally, Principal Financial Group Inc. lifted its position in Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after purchasing an additional 6,973 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Trading Up 1.3 %

SVRA stock opened at $4.05 on Friday. The company has a current ratio of 14.90, a quick ratio of 14.90 and a debt-to-equity ratio of 0.22. The firm has a market cap of $559.67 million, a P/E ratio of -10.95 and a beta of 1.00. Savara has a 1-year low of $3.12 and a 1-year high of $5.70. The business’s 50 day moving average is $4.28 and its 200-day moving average is $4.63.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Equities analysts anticipate that Savara will post -0.41 earnings per share for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.